Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to the company’s Quality...

Alvotech has been informed by the U.S. Food and Drug Administration (FDA) that the responses provided to the FDA Form 483 on April 3, 2023, following the conclusion of the reinspection of the company’s Reykjavik facility on March 17, 2023, are currently under review.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug...

Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the Board of Directors has resolved to increase the Company´s share capital by an amount of one-hundred-and-forty-tho

Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the...

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara® Marketing applications for AVT04 have been...

Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

Alvotech (Nasdaq: ALVO) and Landsbankinn hf. have updated their market making agreement, which has been in effect since Alvotech’s shares were admitted to trading in Iceland on June 23, 2022. The...